Skip to main content

Table 3 Efficacy evaluation of sintilimab

From: Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial

Efficacy evaluation

n

%

CR

0

0

PR

17

85.0%

SD

3

15.0%

PD

0

0

ORR (95% CI)

17

85.0% (95% CI: 62.1–96.8%)

DCR (95% CI)

20

100.0% (95% CI: 83.2–100.0%)

  1. CI confidence interval, CR complete response, DCR disease control rate, ORR overall response rate, PD progressive disease, PR partial response, SD stable disease
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us